Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection.
Human papillomavirus infection is one of the most common and most distressing cutaneous diseases in patients with HIV infection. It is also a common, and often therapeutically challenging, infection in individuals who are immunologically competent. A wide range of therapeutic options exists for treating cutaneous human papillomavirus infections, but none is uniformly effective. In this report we describe a man with HIV-1 infection and disfiguring facial verruca vulgaris who demonstrated complete clinical response to intravenous cidofovir. Our report provides further support for the use of intravenous cidofovir as therapy for treatment-resistant and/or widespread cutaneous human papillomavirus infection.
Kottke
Margaret D
MD
Emory University School of Medicine, Department of Dermatology, Atlanta, Georgia, USA.
Parker
Sareeta R S
SR
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000473:pathology; D017193:Skin Diseases, Viral / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir